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Editorial Comment 
Myocardial Metabolism by severity (fasting, ischemic protocol) or for advanced disease 
Positron Emission Tomography in 
after myocardial infarction (glucose-loaded, viability proto- 
col). 
Hypertrophic Cardiomyopathy* The use of metabolic tracers in hypertrophic cardiomy- 
opathy suggests new applications of these positron tracers. 
Using positron emission tomography, Grover-McKay et al. 
esis and the observations of Grover-McKay et al. (1) may be 
(I), in this issue of the Journal, report that the hypertrophied 
the earlier discovery by Merhige et al. (3) in this laboratory 
septum of patients with hypertrophic cardiomyopathy fails 
that stimulation of catecholamines, specifically dopamine, 
to take up the glucose analogue F-18 fluorodeoxyglucose 
suppresses fluorodeoxyglucose uptake in the heart. Further- 
despite normal uptake in the rest of the myocardium, normal 
more, in experimental animals, dopamine suppression of 
uptake of the fatty acid tracer, C-l I palmitate and normal or 
cardiac fluorodeoxyglucose uptake is reversed to myocardial 
only mildly reduced myocardial perfusion. The septum is 
uptake by beta-blockade as shown in Figure 1. 
therefore viable and not ischemic at rest but is metabolically 
However, in hypertrophic cardiomyopathy, we have ob- 
different from normal myocardium. This report is an impor- 
served that neither glucose loading nor beta-blockade stim- 
tant one because it describes an interesting new scientific 
ulates uptake of fluorodeoxyglucose in the hypertrophied 
observation in humans and highlights the importance of septum, whereas these conditions cause uptake of this tracer 
clinical positron emission tomography. in other normal parts of the heart. The absence of fluoro- 
Myocardial metabolism in the normal heart and in hyper- deoxyglucose uptake in the septum of patients with hyper- 
trophic cardiomyopathy. Myocardial glucose metabolism is trophic cardiomyopathy despite strong enough stimuli for its 
regulated primarily by serum fatty acid levels and oxygen uptake elsewhere in the heart suggests a primary septal 
availability (2). In the fasting state, when serum fatty acid metabolic abnormality unrelated to ischemia or substrate 
levels are high, myocardial glucose uptake is suppressed availability. 
except in ischemic tissue, where lack of oxygen causes Mechanisms. These hypertrophied septa appear to be 
anaerobic glycolysis. Therefore, for identifying myocardial regionally resistant to glucose and insulin. The question is by 
ischemia, we carry out cardiac positron imaging with fluo- what mechanism? Two alternatives stand out. There may be 
rodeoxyglucose in the fasting state when ischemic viable a defective insulin receptor restricted to the cardiac septa of 
myocardium traps fluorodeoxyglucose but necrotic and nor- such patients, causing a localized “diabetic cardiomyopa- 
mal myocardium do not. After an oral gllrcose load, both thy” consistent with excessive glycogen stores in hypertro- 
normal and ischemic myocardium take up fluorodeoxyglu- phic cardiomyopathy (4), as also seen in global cardiomyop- 
case but not necrotic tissue. Therefore, for identifying viable athy of diabetic patients. 
versus necrotic myocardium, we obtain positron images of An alternative possibility is that beta receptors or the 
fluorodeoxyglucose after oral glucose load, which, however, symputhetic nen~ous system in the septum or both, may be 
do not distinguish between normal and ischemic tissue. We defective with inadequate or ineffective catecholamine 
use one or both of these protocols for clinical purposes to mechanisms. Systemically in vivo. increased catechol- 
decide on interventions for coronary stenosis of equivocal amines cause lipolysis and an increase in serum fatty acid 
that suppresses cardiac glucose uptake: this mechanism 
probably explains the observation by Merhige et al. (3) 
*Editorials published in .Ioumc~/ of thu Amvkm~ Cdege of Cdiolo~.~ 
reflect the views of the authors and do not necessarily represent the views of 
because cardiac glucose uptake is inversely related to serum 
JACC or the American College of Cardiology. fatty acids in normal hearts. However, in isolated perfused 
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The cause for regional hypertrophy in hypertrophic cardio- 
myopathy has not been identified. Although thought to be 
related to excessive local catecholamines or beta-adrenergic 
receptors, little direct evidence for this conjecture has been 
available in vivo. A link between the catecholamine hypoth- 
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In hypertrophic cardiomyopathy, defective or inadequate 
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catechol stimulation regionally in the septum might explain 
MSMB. University of Texas Medical Sch% at Houston. Houston. Texac in part the excessive stores of glycogen and failure of glucose 
77925. uptake under conditions in which normal myocardium uti- 
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Figure 1. Positron emission tomographs of fluorodeoxyglucose in- 
jected intravenously in a dog. The upper images show skeletal 
muscle uptake and no cardiac uptake during glucose loading and 
dopamine infusion. The lower images show myocardial uptake of 
fluorodeoxyglucose and suppressed skeletal muscle uptake with the 
same glucose loading and dopamine infusion but with beta blockade 
by propranolol. The cardiac images fit within the paraspinal skeletal 
muscle uptake seen in the upper images. 
lizes glucose or breaks down glycogen. The presence of 
excessive local catecholamines in the septum of hypertro- 
phic cardiomyopathy might be consistent with this possibil- 
ity if their removal or utilization were impaired. Because 
parts of the cardiac septum are derived embryonically from 
neural crest tissue, a genetic basis for hypertrophic cardio- 
myopathy might be reasonably related to regionally defec- 
tive catechol function. 
Although not ischemic at rest, the hypertrophic myocar- 
dium may become ischemic during stress in some patients 
because of limited coronary flow reserve as evidenced by 
chest pain and electrocardiographic changes. If the septum 
were unable to utilize fatty acids because of ischemia and 
were also unable to metabolize glucose because of a primary 
metabolic defect, myocardial injury and eventual fibrosis 
might develop as seen in hypertrophic cardiomyopathy. 
However, additional studies are needed to examine these 
possibilities and their mechanisms. 
Clinical positron emission tomography. The identification 
of a primary regional metabolic abnormality in hypertrophic 
cardiomyopathy is an important addition to the growing 
applications of positron emission tomography in clinical 
cardiology that are now being recognized as essential to 
cardiovascular medicine (5,6). Positron imaging of the heart 
is optimal for accurate noninvasive diagnosis of coronary 
artery disease in symptomatic or asymptomatic patients, 
assessing physiologic severity of stenosis, imaging myocar- 
dial infarction, determining myocardial viability, assessing 
the effects of interventions such as thrombolysis or coronary 
angioplasty on coronary Row reserve or of bypass surgery on 
function and metabolism or following noninvasively the 
progression or regression of coronary artery disease during 
risk factor treatment and evaluating collateral flow function 
(5-8). Generator-produced rubidium-82 (5,7) makes positron 
emission tomography economical for routine clinical studies. 
Positron imaging therefore provides a noninvasive physio- 
logic, functional basis for specific therapeutic approaches in 
the management of heart disease, particularly silent or 
symptomatic coronary artery disease, that has not been 
previously available. 
1 am indebted to Michael Merhige, MD, for Figure I and to Heinrich 
Taegtmeyer, MD, Dr. Phil, both of whom provided fruitful discussions in the 
preparation of this editorial. 
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